Drug Trial Radar · NCT06744868
A Single- and Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of THDBH120 Injection in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Dec 19, 2023
Primary completion
Sep 22, 2024
Study completion Sep 22, 2024
Sponsor
- Lead sponsor
- Tonghua Dongbao Pharmaceutical Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study includes single-ascending dose cohorts (SAD cohorts) and multiple-ascending dose cohorts (MAD cohorts). The aim of this trial is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of THDBH120 injection in healthy patients.
Conditions
- Healthy
Interventions
THDBH120 injection (SAD)Drug
Participants received escalating single doses of THDBH120 by subcutaneous injection.
Placebo of THDBH120 injection (SAD)Drug
Participants received single dose of placebo by subcutaneous injection.
THDBH120 injection (MAD)Drug
Participants received multiple doses of THDBH120 once weekly for four weeks by subcutaneous injection.
Placebo of THDBH120 injection (MAD)Drug
Participants received placebo once weekly for four weeks by subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with One or More Adverse Event(s) and Serious Adverse Event(s)Time frame: From the first drug administration to the follow-up visit (57 days after the last drug administration)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.